Prostate Cancer Clinical Trial

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Summary

The purpose of this study is to determine if Prostate-Specific Membrane Antigen (PSMA) positron emission tomography (PET) scans used in this study accurate and better at imaging participants' prostate cancer than the usual methods.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with histologically confirmed prostate cancer, that is either: newly diagnosed OR progressive as defined by standard PCWG3 criteria. note that metastatic disease is defined by either bone scintigraphy or by CT or MRI, or a combination of these tests, but not exclusively by molecular imaging criteria.

Patients with newly diagnosed localized or metastatic prostate cancer are eligible, provided standard imaging (either bone scintigraphy, CT or MRI) demonstrates evidence of radiographic disease

Patient with progressive disease that is non-metastatic are eligible by biochemical progression: A minimum of three rising PSA values from a baseline that are obtained 1 week or more apart, or 2 measurements 2 or more weeks apart

Patients with progressive disease that is metastatic are eligible either by biochemical progression or radiographic progression or both

Patients are permitted to have had up to 2 months of prior hormonal therapy before entering this trial (and many therapeutic trials) and therefore, their progression criteria would apply to their pre-treatment imaging and PSA parameters Note: This criterion pertains to patients with newly diagnosed, untreated disease. This criterion does not apply to those who were already on therapy for metastatic CRPC.

Karnofsky performance status of >/= 50 (or ECOG/WHO equivalent)
Male (or transgender female) > 18 years of age
Patient must be able to understand and willing to sign a written informed consent document
Patient is anticipating starting a therapeutic strategy following imaging

Exclusion Criteria:

Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and non-invasive bladder cancer
Unable to lie flat, still or tolerate a PET scan

Study is for people with:

Prostate Cancer

Estimated Enrollment:

600

Study ID:

NCT04030338

Recruitment Status:

Recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Memorial Sloan Kettering Basking Ridge
Basking Ridge New Jersey, 07920, United States More Info
Heiko Schöder, MD
Contact
212-639-2079
Memorial Sloan Kettering Monmouth
Middletown New Jersey, 07748, United States More Info
Heiko Schoder, MD
Contact
212-639-2079
Memorial Sloan Kettering Bergen
Montvale New Jersey, 07645, United States More Info
Heiko Schoder, MD
Contact
212-639-2079
Memorial Sloan Kettering Commack
Commack New York, 11725, United States More Info
Heiko Schöder, MD
Contact
212-639-2079
Memorial Sloan Kettering Westchester
Harrison New York, 10604, United States More Info
Heiko Schoder, MD
Contact
212-639-2079
Memorial Sloan Kettering Cancer Center
New York New York, 10021, United States More Info
Heiko Schoder, MD
Contact
212-639-2079
Memorial Sloan Kettering Nassau
Uniondale New York, 11553, United States More Info
Heiko Schoder, MD
Contact
212-639-2079

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

600

Study ID:

NCT04030338

Recruitment Status:

Recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.